Michal Izrael

1st January, 1970

Michal Izrael

Dr‭. ‬Izrael Joined Kadimastem in 2009‭. ‬Prior to joining Kadimastem‭, ‬as part of her doctoral work at the Weizmann Institute of Science in the laboratory of Prof‭. ‬Revel‭, ‬Dr‭. ‬Izrael was a central part of the team that invented and developed the technology which became the basis for Kadimastem’s cell therapy product for Amyotrophic Lateral Sclerosis‭ (‬ALS‭) ‬and other neurodegenerative diseases‭. ‬At Kadimastem she served as‭ ‬the head of the drug screening team‭, ‬based on human oligodendrocytes‭ (‬Myeling forming cells‭), ‬and in 2012‭ ‬was appointed to run‭ ‬the neurodegenerative department at Kadimastem‭, ‬responsible for Kadimastem’s cell product for ALS‭. ‬In 2017‭ ‬she was appointed as VP for Research and Development for ALS and Neurodegenerative Diseases‭. ‬Dr‭.‬‭ ‬Izrael holds a PhD in molecular genetics from the Weizmann Institute of Science and M.Sc‭. ‬in Neurobiology from the Hebrew University of Jerusalem‭. ‬Dr‭. ‬Izrael has published 16‭ ‬scientific papers and patents in the field of neurobiology and development of technologies based on stem cell derivatives for the treatment of central nervous system disease and drug screening‭.


Arena’s business-to-business events offer a myriad of opportunities for sponsors and exhibitors to drive their businesses forward.
Our sponsorship packages help companies educate ther target market on key industry issues and spread brand awareness throughout the

If you want to discuss how we can help you generate leads and add-value to your corporate and brand image please contact:

Paul Adams
+44 (0)20 7936 6948

Speaker opportunities

We identify and invite individuals we believe to be the best speakers in the market, if you think you can make a difference to the quality of our events please contact:

Chloe Roberts
E: Chloe.Roberts@arena-international.com
T: +44 (0)207 936 6822